document
reflect
emerg
clinic
scientif
advanc
date
issu
subject
chang
inform
constru
dictat
exclus
cours
treatment
procedur
follow
local
institut
dictat
amend
opinion
well
document
modifi
local
level
none
content
may
reproduc
form
without
prior
written
permiss
sogc
nfectiou
complic
follow
gynaecolog
surgic
procedur
signific
sourc
morbid
potenti
mortal
includ
urinari
tract
infect
endometr
wound
infect
vagin
cuff
cellul
perin
infect
sepsi
lead
prolong
hospit
stay
increas
health
care
cost
much
work
done
studi
effect
prophylact
antibiot
reduc
infecti
morbid
plethora
antibiot
type
dose
schedul
rout
administr
investig
evid
support
use
prophylact
antibiot
number
procedur
gynaecolog
unfortun
compar
trial
conduct
leav
clinician
uncertainti
regimen
superior
presenc
antibiot
resist
organ
realiti
canadian
health
care
facil
organ
includ
methicillin
resist
staphylococcu
aureu
vancomycin
resist
enterococcu
extendedspectrum
betalactamaseproduc
organ
morbid
mortal
increas
infect
involv
organ
may
virul
difficult
treat
therapeut
option
limit
antibiot
resist
develop
result
mainli
inappropri
use
antibiot
incomplet
cours
antibiot
therapi
unnecessari
use
broader
spectrum
regimen
play
role
adher
treatment
prophylaxi
guidelin
like
assist
reduc
infect
antibiot
resist
physician
adher
antibiot
prophylaxi
guidelin
variabl
frequent
odd
publish
guidelin
addit
antibiot
prophylaxi
factor
affect
infecti
risk
reduct
specialti
must
review
steril
surgic
field
must
ensur
ongo
qualiti
assess
steril
techniqu
air
ventil
postop
wound
care
need
consist
infect
control
surveil
report
infecti
complic
track
abil
minim
morbid
possibl
identifi
cluster
infect
emerg
antibiot
resist
organ
dictat
chang
oper
routin
respond
evolv
microbi
divers
seem
inevit
purpos
antibiot
prophylaxi
surgic
procedur
steril
tissu
reduc
colon
pressur
microorgan
introduc
time
oper
level
patient
immun
system
abl
overcom
prophylaxi
prevent
infect
caus
postop
contamin
prophylact
antibiot
use
differ
treatment
antibiot
former
intend
prevent
infect
wherea
latter
intend
resolv
establish
infect
typic
requir
longer
cours
therapi
prophylaxi
intend
elect
procedur
incis
close
oper
room
agent
consid
use
prophylact
must
evid
reduc
postop
infect
must
also
safe
inexpens
must
effect
organ
like
encount
surgic
procedur
agent
must
administ
way
ensur
serum
tissu
level
adequ
incis
made
therapeut
level
agent
maintain
serum
tissu
prophylact
antibiot
given
administ
shortli
bacteri
inocul
done
minut
skin
incis
major
studi
suggest
singl
dose
effect
lengthi
procedur
hour
dose
repeat
interv
time
halflif
drug
also
suggest
larg
blood
loss
ml
second
dose
given
hysterectomi
consid
class
ii
cleancontamin
wound
metaanalysi
systemat
review
regard
antibiot
prophylaxi
vagin
hysterectomi
review
duff
park
includ
studi
major
prospect
random
trial
mani
doubleblind
without
prophylaxi
incid
febril
morbid
averag
reduc
prophylact
antibiot
type
dose
durat
antibiot
use
highli
variabl
firstgener
cephalosporin
use
major
studi
random
trial
compar
amoxicillinclavulan
acid
cefazolin
n
show
differ
infect
rate
anoth
trial
compar
use
cefuroxim
metronidazol
show
increas
morbid
metronidazol
ad
treat
bacteri
vaginosi
metronidazol
rectal
least
day
prior
vagin
hysterectomi
appear
reduc
incid
vagin
cuff
infect
n
vs
may
impract
given
possibl
surgeri
cancel
also
difficult
comment
costbenefit
screen
women
bv
prior
surgeri
metaanalys
explor
efficaci
antibiot
prophylaxi
abdomin
hysterectomi
recent
tano
rojanski
compar
trial
n
use
singl
dose
hour
intramuscular
intraven
cephalosporin
signific
reduct
incid
infect
treatment
group
ci
febril
morbid
prevent
firstgener
cephalosporin
secondand
thirdgener
choic
author
conclud
singl
dose
firstor
secondgener
cephalosporin
efficaci
costeffect
mittendorf
et
al
metaanalyz
rct
n
vari
antibiot
choic
durat
rout
administr
found
seriou
infect
less
common
treatment
group
vs
p
among
receiv
cefazolin
metronidazol
respect
seriou
postop
infect
lastli
wttewaallevelaar
examin
rct
major
use
firstor
secondgener
cephalosporin
infect
significantli
reduc
treatment
group
p
random
trial
women
undergo
gynaecolog
procedur
via
laparotomi
includ
abdomin
hysterectomi
compar
amoxicillinclavulan
acid
cefazolin
n
show
differ
infect
rate
random
trial
n
compar
placebo
ampicillin
cefazolin
demonstr
signific
superior
cefazolin
reduc
postop
infect
random
studi
compar
singl
dose
versu
regimen
cefuroxim
plu
metronidazol
show
differ
cochran
review
show
laparoscop
hysterectomi
laparoscop
assist
vagin
hysterectomi
laparoscop
subtot
hysterectomi
result
fewer
wound
abdomin
wall
infect
ci
fewer
unspecifi
infect
febril
episod
ci
abdomin
hysterectomi
differ
infect
laparoscop
hysterectomi
vagin
hysterectomi
trial
assess
use
prophylact
antibiot
type
laparoscop
hysterectomi
given
cleancontamin
procedur
rate
postop
infect
similar
vagin
hysterectomi
would
seem
reason
treat
patient
similar
fashion
singl
dose
cefazolin
determin
effect
multipl
dose
studi
women
underw
laparoscop
assist
vagin
hysterectomi
procedur
consid
clean
tabl
genit
tract
enter
random
nonblind
trial
women
undergo
laparoscopi
variou
indic
hysterectomi
found
differ
infect
rate
receiv
singl
dose
cefazolin
studi
assess
prophylact
antibiot
prior
surgeri
without
use
suprapub
cathet
also
studi
regard
isol
suburethr
sling
procedur
eg
transvagin
transobtur
tape
given
poor
outcom
associ
mesh
infect
administr
singl
preoper
dose
firstgener
cephalosporin
common
practic
women
undergo
surgeri
pelvic
organ
prolaps
andor
stress
urinari
incontin
receiv
singl
dose
firstgener
cephalosporin
iiib
cochran
review
prophylact
antibiot
transcerv
intrauterin
procedur
identifi
random
trial
met
criteria
pseudorandom
studi
use
centrespecif
antibiot
prophylaxi
analyz
infertil
women
underw
offic
hysteroscopi
two
hundr
sixtysix
women
receiv
amoxicillinclavulan
doxycyclin
hour
preprocedur
differ
postprocedur
infect
antibiot
group
random
trial
amoxicillin
clavulan
versu
placebo
hysteroscop
ablat
n
found
signific
differ
occurr
bacteremia
vs
howev
author
comment
major
organ
dubiou
clinic
signific
contamin
could
exclud
case
signific
differ
found
women
treat
presum
infect
vs
object
measur
use
case
seri
women
suggest
infect
risk
low
studi
address
prophylact
antibiot
set
hysteroscop
myomectomi
metaanalysi
includ
random
clinic
trial
demonstr
prophylact
antibiot
significantli
reduc
postabort
infect
week
compar
placebo
rel
risk
upper
genit
tract
infect
follow
surgic
abort
ci
antibiot
benefit
seen
women
consid
high
risk
low
risk
infect
thu
author
conclud
univers
prophylaxi
given
placebocontrol
trial
perform
appropri
antibiot
regimen
howev
yet
determin
compar
superior
trial
conduct
largest
trial
date
n
statist
signific
reduct
postop
infect
rate
rr
ci
use
doxycyclin
mg
oral
procedur
follow
mg
procedur
regimen
effect
random
trial
includ
metronidazol
mg
oral
hour
procedur
repeat
hour
procedur
rr
ci
doxycyclin
mg
oral
hour
procedur
rr
ci
costeffect
studi
look
univers
screen
sexual
transmit
infect
versu
prophylact
azithromycin
g
show
prophylact
treatment
provid
signific
cost
save
g
hour
estim
blood
loss
ml
addit
dose
prophylact
antibiot
may
given
hour
initi
dose
iiic
antibiot
prophylaxi
recommend
laparoscop
procedur
involv
direct
access
abdomin
caviti
uterin
caviti
vagina
ie
flora
bv
rr
untreat
group
ci
anoth
random
blind
trial
found
give
singl
g
metronidazol
suppositori
preoper
women
confirm
bacteri
vaginosi
make
signific
differ
rr
p
screen
treat
bacteri
vaginosi
prior
surgeri
also
may
impract
costeffect
known
two
random
placebocontrol
trial
assess
effect
prophylact
antibiot
reduc
infecti
morbid
follow
uterin
evacu
incomplet
abort
one
trial
involv
women
use
preoper
intraven
dose
doxycyclin
placebo
chlamydia
gonorrhea
rate
low
popul
differ
postop
infecti
morbid
rate
occur
week
postprocedur
second
studi
women
investig
use
mg
oral
doxycyclin
minut
preprocedur
signific
differ
group
found
variou
author
demonstr
risk
iudrel
infect
limit
first
week
month
insert
therefor
like
relat
contamin
endometri
caviti
time
insert
rather
iud
string
cochran
review
includ
random
control
trial
found
differ
occurr
pid
iud
insert
patient
given
prophylact
doxycyclin
azithromycin
given
placebo
ci
use
antibiot
also
affect
whether
iud
remov
within
day
insert
ci
howev
patient
consid
high
risk
sexual
transmit
infect
would
reason
consid
screen
iud
placement
antibiot
prophylaxi
recommend
insert
intrauterin
devic
ie
howev
health
care
profession
could
consid
screen
sexual
transmit
infect
highrisk
popul
iiic
studi
assess
use
prophylact
antibiot
given
endometri
biopsi
procedur
consid
standard
care
insuffici
evid
support
use
antibiot
prophylaxi
endometri
biopsi
iiil
mani
option
prevent
infect
may
occur
result
hsg
univers
screen
sti
could
carri
patient
treat
necessari
patient
high
risk
determin
histori
could
screen
patient
could
receiv
prophylact
antibiot
antibiot
could
given
patient
high
risk
determin
histori
andor
indic
presenc
tubal
obstruct
time
hsg
mani
patient
may
alreadi
screen
perform
part
infertil
workup
infect
found
treatment
follow
canadian
guidelin
sti
prospect
studi
investig
option
retrospect
studi
found
among
women
receiv
antibiot
incid
pid
hsg
patient
dilat
tube
patient
dilat
tube
develop
infect
second
group
patient
n
receiv
singl
dose
oral
doxycyclin
hsg
patient
includ
dilat
tube
develop
pid
studi
suggest
incid
pid
normal
tube
low
regardless
prophylact
antibiot
highestrisk
group
women
dilat
tube
time
hsg
benefit
prophylact
doxycyclin
best
method
prevent
infect
hysterosalpingographi
unknown
women
dilat
tube
found
time
hysterosalpingographi
highest
risk
prophylact
antibiot
eg
doxycyclin
given
systemat
review
includ
rct
patient
women
prophylact
antibiot
differ
type
dose
durat
compar
either
placebo
treatment
author
note
trial
poor
methodolog
conclud
reduct
risk
bacteriuria
ci
correl
number
need
treat
studi
assess
occurr
bacteriuria
symptomat
uti
therefor
clinic
signific
unknown
estim
women
develop
symptomat
uti
within
week
diagnosi
asymptomat
bacteriuria
basi
result
decisionanalysi
incorpor
reason
estim
benefit
advers
event
publish
literatur
author
conclud
prophylact
antibiot
urodynam
women
low
risk
administ
background
rate
uti
urodynam
without
prophylaxi
higher
antibiot
prophylaxi
recommend
urodynam
studi
women
low
risk
unless
incid
urinari
tract
infect
posturodynam
increas
bmi
associ
higher
rate
surgic
infecti
complic
expert
opinion
recommend
twice
normal
dose
prophylaxi
morbidli
obes
patient
bmi
kmm
howev
control
trial
assess
requir
dosag
antibiot
prophylaxi
base
patient
bmi
assess
specialti
futur
research
need
patient
morbid
obes
bmi
kgm
doubl
antibiot
dose
may
consid
iiib
penicillin
allergi
selfreport
patient
yet
report
allerg
allerg
skin
test
perform
true
anaphylact
respons
penicillin
rare
occur
per
administr
allerg
reaction
cephalosporin
occur
rate
penicillin
allergi
altern
prophylact
antibiot
deem
truli
penicillin
allerg
includ
clindamycin
mg
iv
erythromycin
mg
iv
american
heart
assoc
guidelin
publish
found
evid
genitourinari
procedur
caus
infecti
endocard
administr
antibiot
prevent
infecti
endocard
follow
procedur
american
heart
assoc
therefor
recommend
prophylact
antibiot
patient
undergo
genitourinari
procedur
chang
american
heart
assoc
guidelin
guidelin
identifi
condit
highest
risk
advers
outcom
tabl
patient
condit
list
tabl
establish
gastrointestin
genitourinari
infect
receiv
antibiot
therapi
anoth
reason
eg
prevent
wound
infect
may
reason
antibiot
use
also
activ
enterococci
ampicillin
piperacillin
vancomycin
guidelin
also
suggest
may
reason
patient
high
risk
infecti
endocard
known
enterococc
urinari
tract
infect
colon
receiv
antibiot
treatment
prior
urinari
tract
manipul
review
recommend
chang
recent
publish
administr
antibiot
sole
prevent
endocard
recommend
patient
undergo
genitourinari
procedur
iiie
number
procedur
gynaecolog
use
prophylact
antibiot
shown
reduc
infecti
morbid
safe
costeffect
manner
tabl
remain
number
procedur
util
prophylact
antibiot
either
unclear
studi
appropri
antibiot
use
correct
dose
time
appropri
frequenc
reduc
infecti
postop
complic
minim
develop
antibiot
resist
organ
